Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in Argentina

Total 635 results

Hospital Italiano de Buenos Aires

Unknown

Hospitalary Chronic Obstructive Pulmonary Disease Registry

Death | COPD Exacerbations

Argentina
Novartis Pharmaceuticals

Completed

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (Advantage)

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Korea, Republic of, Argentina, Canada, India, Bulgaria, Poland
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Czechia, Denmark, Hungary, Netherlands, Spain, Korea, Republic of, Argentina, Belgium, Bulgaria, Finland, India, Japan, Mexico, Norway, Sweden, Turkey, Vietnam, Portugal, Puerto Rico
AstraZeneca

Recruiting

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PROSPERO)

Chronic Obstructive Pulmonary Disease (COPD)

China, Denmark, United States, Australia, Germany, Netherlands, Poland, Spain, United Kingdom, Korea, Republic of, Philippines, Italy, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Hungary, India, Japan, Mexico, Norway, Port... and more
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA)

Chronic Obstructive Pulmonary Disease (COPD)

China, United States, Denmark, Italy, Germany, Hungary, Netherlands, Spain, United Kingdom, Belgium, Argentina, Bulgaria, Canada, India, Japan, Vietnam, Brazil, Malaysia, Thailand, France, Mexico, Greece, Poland, Korea, Republic of, Peru, Chil... and more
AstraZeneca

Completed

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, France, Italy, Spain, Turkey, United Kingdom, Germany, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Greece, Ireland, Switzerland
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
AstraZeneca

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

COPD (Chronic Obstructive Pulmonary Disease)

France, Denmark, Italy, Spain, United States, Canada, Argentina, Japan, Colombia, Germany, Peru, Brazil, China, India, Thailand, Austria, Serbia, Malaysia, Philippines, Poland, Taiwan, Greece, Norway, Sweden, Mexico, Romania, Korea, Republic... and more
Hoffmann-La Roche

Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, China, Spain, Italy, Germany, Belgium, Korea, Republic of, Poland, Taiwan, Israel, New Zealand, Sweden, United Kingdom, Japan, Czechia, Philippines, Hong Kong, Greece, Australia, Thailand, Netherlands, Argentina, Brazil, Fran... and more
Hospital Italiano de Buenos Aires
Asociacion Argentina Medicina Respiratoria (AAMR)

Unknown

Association Between Testosterone Levels and COPD Severity (COPDTESTO)

Chronic Obstructive Pulmonary Disease | Hypogonadism

Argentina
AstraZeneca

Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Lung Diseases | Pulmonary Disease | COPD | COPD Exacerbation | Respiratory Disorders | Chronic Obstructive Airway Disease | Chronic Obstructive Lung Diseases

United States, Argentina, Canada, Chile, Colombia, Italy, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Serbia, Spain, Taiwan, Thailand, Ukraine
AstraZeneca

Completed

Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America (PUMA PROJECT)

Chronic Obstructive Pulmonary Disease

Venezuela, Colombia, Argentina, Uruguay
Novartis

Completed

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | COPD

United States, Germany, Spain, Argentina, Italy, Turkey, Canada, India, Sweden, Korea, Republic of, Taiwan, Puerto Rico
GlaxoSmithKline

Completed

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Chile, South Africa, New Zealand
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Germany, Spain, United States, China, Korea, Republic of, Argentina, United Kingdom, Canada
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
AstraZeneca
Parexel

Completed

Observational Study of Obstructive Lung Disease (NOVELTY) (NOVELTY)

Chronic Obstructive Pulmonary Disease | Asthma | COPD

United States, Canada, Germany, Italy, Spain, United Kingdom, Mexico, Australia, Argentina, France, China, Japan, Brazil, Korea, Republic of, Colombia, Denmark, Netherlands, Norway, Sweden
Chiesi Farmaceutici S.p.A.

Recruiting

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

COPD | COPD Exacerbation

United States, Bulgaria, Hungary, Poland, Argentina, Czechia, Mexico, Canada, Puerto Rico, Romania
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Novartis Pharmaceuticals

Completed

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (COMBINE)

Chronic Obstructive Pulmonary Disease

Argentina, Dominican Republic, Panama, Mexico, Brazil, Chile, Ecuador, Honduras
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Canada, Bulgaria, Hungary, Russian Federation, Denmark, Argentina, Mexico, Poland
Novartis Pharmaceuticals

Completed

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)

Chronic Obstructive Pulmonary Disease

Colombia, Italy, Switzerland, Argentina, United Kingdom, Mexico, Netherlands, Malaysia, Spain
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
Novartis

Completed

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Chronic Obstructive Pulmonary Disease

Russian Federation, United Kingdom, Spain, Germany, Argentina, Italy, Netherlands, Switzerland, Turkey, France, Czech Republic, Hungary, Slovakia, Peru, Korea, Republic of, Colombia, Israel, Chile, Denmark, Ecuador, Egypt, Estonia, ... and more
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Belgium, Australia, Israel, Spain, France, United Kingdom, Denmark, Argentina, Germany, New Zealand, South Africa, Korea, Republic of, Poland, Bulgaria, Canada, Chile, Czechia, Netherlands, Romania, Sweden, Mexico
Novartis Pharmaceuticals

Completed

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

Chronic Obstructive Pulmonary Disease

Germany, United States, Colombia, Poland, South Africa, Canada, Estonia, Hungary, India, Austria, Israel, Netherlands, United Kingdom, Argentina, France, Italy, Spain, Czech Republic, Denmark, Finland, Greece, Ireland, Mexico, Peru, Phi... and more
Genentech, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States, Israel, Australia, Denmark, Korea, Republic of, Spain, Belgium, France, Bulgaria, Poland, United Kingdom, Germany, Canada, Netherlands, Peru, Argentina, Hong Kong, South Africa, New Zealand, Sweden, Czechia, Austria, ... and more
AstraZeneca

Active, not recruiting

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE)

Chronic Obstructive Pulmonary Disease

United States, Austria, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Belgium, Vietnam, Brazil, Hungary, Philippines, China, Korea, Republic of, Argentina, Australia, Poland, Turkey, Japan, Greece, Netherlands, Czechia, Mexico, Bulgar... and more
GlaxoSmithKline

Completed

Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Spain, Chile, Germany, Korea, Republic of, Bulgaria, Brazil, Slovakia
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more

Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations